Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by tylerreddickon Apr 16, 2024 1:24pm
58 Views
Post# 35991919

RE:RE:RE:RE:RE:New 52 week low

RE:RE:RE:RE:RE:New 52 week low
forhandlaren wrote: Worst case they can always sell a project, like the Abbvie contract.

There will not be a default since there are unleashed value in the projects and scientific platform.

The first sell-off was triggered by the private placement that was reckless to launch just after securing a loan and positive NR round the corner. The management should be blamed.

For some strange reason people started to sell triggered by the AGM, which is a non-event. There hasn't been any material NR in conjunction to the AGM and it will never be. This one is on us as shareholders.

But in the end of the day there's good enough value in the company to ensure most if not all investors to end up even in the worst case. The share price does not reflect current value.



So why aren't you buying?
<< Previous
Bullboard Posts
Next >>